Biogen Inc. (BIIB) Shares Bought by Bp Plc

Bp Plc raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 14.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,000 shares of the biotechnology company’s stock after purchasing an additional 6,000 shares during the period. Bp Plc’s holdings in Biogen were worth $15,021,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Guardian Life Insurance Co. of America boosted its stake in shares of Biogen by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 6 shares during the period. Carroll Financial Associates Inc. boosted its stake in Biogen by 1.2% during the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 6 shares during the last quarter. RMB Capital Management LLC boosted its stake in Biogen by 1.1% during the 1st quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 9 shares during the last quarter. New Amsterdam Partners LLC NY boosted its stake in Biogen by 0.8% during the 2nd quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 11 shares during the last quarter. Finally, American Money Management LLC boosted its stake in Biogen by 1.0% during the 1st quarter. American Money Management LLC now owns 1,349 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 14 shares during the last quarter. 87.71% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/02/biogen-inc-biib-shares-bought-by-bp-plc.html.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.19 EPS.

BIIB has been the topic of a number of research reports. Citigroup Inc. cut shares of Biogen from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Vetr cut shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 target price on the stock. in a report on Wednesday, August 23rd. Stifel Nicolaus reissued a “hold” rating and set a $300.00 target price on shares of Biogen in a report on Thursday, October 12th. Robert W. Baird reissued a “hold” rating and set a $290.00 target price on shares of Biogen in a report on Friday, August 25th. Finally, Morgan Stanley reissued a “buy” rating on shares of Biogen in a report on Tuesday, October 17th. Twelve analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $341.25.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply